Sanofi Current Ratio 2010-2023 | SNY
Current and historical current ratio for Sanofi (SNY) from 2010 to 2023. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Sanofi current ratio for the three months ending December 31, 2023 was 1.27.
| Sanofi Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2023-12-31 |
$33.19B |
$26.19B |
1.27 |
| 2023-09-30 |
$0.00B |
|
0.00 |
| 2023-06-30 |
$32.69B |
$27.00B |
1.21 |
| 2023-03-31 |
$0.00B |
|
0.00 |
| 2022-12-31 |
$35.85B |
$25.25B |
1.42 |
| 2022-09-30 |
$0.00B |
|
0.00 |
| 2022-06-30 |
$30.18B |
$23.48B |
1.29 |
| 2022-03-31 |
$0.00B |
|
0.00 |
| 2021-09-30 |
$0.00B |
|
0.00 |
| 2021-06-30 |
$35.55B |
$23.05B |
1.54 |
| 2021-03-31 |
$0.00B |
|
0.00 |
| 2020-09-30 |
$0.00B |
|
0.00 |
| 2020-03-31 |
$0.00B |
|
0.00 |
| 2019-09-30 |
$0.00B |
|
0.00 |
| 2019-03-31 |
$0.00B |
|
0.00 |
| 2018-03-31 |
$0.00B |
|
0.00 |
| 2017-12-31 |
$29.79B |
$17.47B |
1.71 |
| 2017-09-30 |
$0.00B |
|
0.00 |
| 2017-06-30 |
$29.78B |
$18.76B |
1.59 |
| 2017-03-31 |
$0.00B |
|
0.00 |
| 2016-12-31 |
$29.53B |
$18.19B |
1.62 |
| 2016-09-30 |
$0.00B |
|
0.00 |
| 2016-06-30 |
$25.23B |
$17.22B |
1.47 |
| 2016-03-31 |
$0.00B |
|
0.00 |
| 2015-09-30 |
$0.00B |
|
0.00 |
| 2015-06-30 |
$24.35B |
$18.03B |
1.35 |
| 2014-06-30 |
$27.94B |
$19.48B |
1.43 |
| 2013-06-30 |
$27.17B |
$17.80B |
1.53 |
| 2012-06-30 |
$27.56B |
$20.66B |
1.33 |
| 2012-03-31 |
$0.00B |
|
0.00 |
| 2011-12-31 |
$29.05B |
$18.92B |
1.54 |
| 2011-09-30 |
$0.00B |
|
0.00 |
| 2011-06-30 |
$32.57B |
$23.10B |
1.41 |
| 2011-03-31 |
$0.00B |
|
0.00 |
| 2010-12-31 |
$35.96B |
$15.62B |
2.30 |
| 2010-09-30 |
$0.00B |
|
0.00 |
| 2010-06-30 |
$31.89B |
$15.40B |
2.07 |
| 2010-03-31 |
$0.00B |
|
0.00 |
| 2009-12-31 |
$33.30B |
$17.29B |
1.93 |
| 2009-09-30 |
$0.00B |
|
0.00 |
| 2009-06-30 |
$25.23B |
$14.69B |
1.72 |
| 2009-03-31 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$124.861B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
